We acknowledge funding, past and present, from the following funding bodies and pharmaceutical companies:
European Union
European Research Council (ERC) Consolidator Grant (CoG): 2017–>
European Research Council (ERC) Starting Grant (StG): 2009-2014
Swiss Federal Government
Swiss National Science Foundation (SNSF): 2012–>
Swiss National Science Foundation (SNSF): SINERGIA 2020–>
National Centres of Competence in Research (NCCR): 2012–>
Other Swiss foundations/agencies/charities
Swiss Cancer League (Oncosuisse): 2012–>
Carigest: 2022–>
Leenaards Foundation: 2014-2016
San Salvatore Foundation: 2014-2015
Fondation Chercher et Trouver (lung cancer foundation)
Anna Fuller Fund
Swiss Bridge Foundation
Fondation pour la lutte contre le cancer
School of Life Sciences – EPFL (intramural funding)
Industry
EVIR Therapeutics: 2021–>
Roche: 2013–>
Deciphera Pharmaceuticals: 2016–>
Medimmune: 2012-2013